At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 50 enrolled
Drug / intervention
sugammadex +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Blinded-assessor, Single Center Study to Determine if Administration of Sugammadex, When Used to Reverse Deep Neuromuscular Blockade (NMB) After Open Abdominal Surgery, Impacts Hospital Efficiency
In Brief
A Phase 4 clinical trial evaluating sugammadex, Neostigmine, and 1 other intervention for Neuromuscular Blockade. Completed, enrolled 50 participants.
Detailed Summary
The purpose of this study is to evaluate the efficacy of Sugammadex in rapidly reversing deep neuromuscular blockaded (induced by rocuronium)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuromuscular Blockade
Countries--
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartAug 2016
First PostedAug 2016
Primary CompletionFeb 2018
TodayJul 2026
First PostedAug 9, 2016
Enrollment StartAug 1, 2016
Primary CompletionFeb 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 9.9 years ago
Interventions
sugammadexdrug
Neostigminedrug
Glycopyrrolatedrug